查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1911928

丙型肝炎治疗药物市场规模、份额和成长分析（按药物类别、给药途径、疾病类型和地区划分）—产业预测（2026-2033 年）

Hepatitis C Drugs Market Size, Share, and Growth Analysis, By Drug Class (direct acting antiviral (NS3/4A protease inhibitor, NS5A inhibitor)), By Routes of Administration (oral, injectable), By Disease Type, By Region- Industry forecast 2026-2033.
出版日期: | 出版商: SkyQuest | 英文 198 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计到 2024 年，全球丙型肝炎治疗市场规模将达到 130.3 亿美元，到 2025 年将达到 135.7 亿美元，到 2033 年将达到 188.6 亿美元，在 2026 年至 2033 年的预测期内，复合年增长率为 4.2%。

受大众意识提升、诊断技术进步以及高效治疗方法涌现的推动，全球丙型肝炎治疗市场正经历强劲成长。丙型肝炎感染率在不同人群中的显着上升，推动了对强效抗病毒疗法的需求，尤其考虑到该疾病可能导致严重的慢性肝病。世界各国政府和医疗机构为根除C型肝炎所做的努力，进一步加速了市场扩张。老年人的高感染率凸显了先进治疗方案的紧迫性。公共卫生倡议正积极进行针对高风险族群的疾病及现有治疗方法的教育。技术创新，特别是直接抗病毒药物（DAA）的创新，透过泛基因型覆盖和固定剂量组合药物，提高了全球治疗的可及性，从而改变了治疗格局，实现了高治癒率和更高的治疗遵守用药。

丙型肝炎治疗市场按药物类别、给药途径、疾病类型和地区进行细分。依药物类别划分，可分为直接抗病毒药物（NS3/4A蛋白酶抑制剂、NS5A抑制剂、NS5B聚合酵素抑制剂）、联合治疗、干扰素和其他药物。依给药途径划分，可分为口服、注射及其他途径。依疾病类型划分，可分为慢性C型肝炎和急性C型肝炎。依地区划分，可分为北美、欧洲、亚太、拉丁美洲以及中东和非洲。

全球丙型肝炎药物市场成长要素

丙型肝炎在全球日益流行，其主要驱动因素包括静脉注射毒品和医疗实践不规范等，这大大增加了对有效治疗方法的需求。人们对这种疾病的认识不断提高，而丙型肝炎的发病机制又与多种风险因素和生活方式的改变密切相关，这进一步凸显了创新治疗方案的紧迫性。随着越来越多的患者被诊断并寻求治疗，医疗系统面临着提供可近且有效治疗的挑战。此外，人们对早期发现和治疗重要性的认识不断提高，正在推动新型治疗方案的研发和广泛应用，从而带动丙型肝炎治疗市场的发展。

限制全球丙型肝炎药物市场的因素

阻碍丙型肝炎广泛治疗的一大挑战是直接抗病毒药物（DAA）的高成本，尤其是在财政资源有限的地区。许多医疗卫生系统面临严重的预算限制，严重阻碍了全民获得治疗。儘管加强竞争和与政府机构的价格谈判在一定程度上降低了药物价格，但这些措施往往不足以使所有需要的患者都能负担得起这些药物。因此，丙型肝炎药物的经济负担仍是全球有效治疗的一大障碍。

全球丙型肝炎治疗市场趋势

全球丙型肝炎治疗市场正经历一场变革，其特点是价格低廉的直接抗病毒药物（DAA）和非专利处方药的供应日益充足。随着多种原厂DAA专利到期以及自愿授权框架的扩展，中低收入国家正迎来大量低成本治疗选择。这种向高性价比治疗方法的转变对于加速治疗普及至关重要，并最终有助于实现消除丙型肝炎的全球卫生目标。此外，提高这些治疗的可近性具有更大的公共卫生意义，有助于改善健康结果，并在对抗丙型肝炎的斗争中扩大人群覆盖范围。

目录

介绍

  • 调查目标
  • 调查范围
  • 定义

调查方法

  • 资讯收集
  • 二手资料和一手资料方法
  • 市场规模预测
  • 市场假设与限制

执行摘要

  • 全球市场展望
  • 供需趋势分析
  • 细分市场机会分析

市场动态与展望

  • 市场规模
  • 市场动态
    • 驱动因素和机会
    • 限制与挑战
  • 波特分析

关键市场考察

  • 关键成功因素
  • 竞争程度
  • 关键投资机会
  • 市场生态系统
  • 市场吸引力指数（2025）
  • PESTEL 分析
  • 总体经济指标
  • 价值链分析
  • 定价分析
  • 案例研究
  • 顾客购买行为分析

全球C型肝炎药物市场规模（依药物类别划分）及复合年增长率（2026-2033 年）

  • 直接作用抗病毒药物
    • NS3/4A蛋白酶抑制剂
    • NS5A抑制剂
    • NS5B聚合酵素抑制剂
  • 联合治疗
  • 干扰素
  • 其他的

全球丙型肝炎药物市场规模（依给药途径及复合年增长率划分）（2026-2033 年）

  • 口服
  • 注射
  • 其他的

全球丙型肝炎药物市场规模（按疾病类型和复合年增长率划分）（2026-2033 年）

  • 慢性C型肝炎
  • 急性C型肝炎

全球丙型肝炎药物市场规模及复合年增长率（2026-2033）

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 西班牙
    • 法国
    • 英国
    • 义大利
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地区
  • 中东和非洲
    • 海湾合作委员会国家
    • 南非
    • 其他中东和非洲地区

竞争资讯

  • 前五大公司对比
  • 主要企业的市场定位（2025 年）
  • 主要市场参与者所采取的策略
  • 近期市场趋势
  • 公司市占率分析（2025 年）
  • 主要企业公司简介
    • 公司详情
    • 产品系列分析
    • 依业务板块进行公司股票分析
    • 2023-2025年营收年比比较

主要企业简介

  • Pfizer（USA）
  • AbbVie（USA）
  • Gilead Sciences（USA）
  • Roche（Switzerland）
  • Johnson and Johnson（USA）
  • Novo Nordisk（Denmark）
  • Hepion Pharmaceutical（USA）
  • Vir Biotechnology（USA）
  • Teva Pharmaceutical（Israel）
  • Bristol Myers Squibb（USA）
  • Merck（USA）
  • AstraZeneca（UK）
  • GlaxoSmithKline（UK）
  • Sanofi（France）

结论与建议

简介目录
Product Code: SQMIG35I2434

Global Hepatitis C Drugs Market size was valued at USD 13.03 Billion in 2024 and is poised to grow from USD 13.57 Billion in 2025 to USD 18.86 Billion by 2033, growing at a CAGR of 4.2% during the forecast period 2026-2033.

The global Hepatitis C drugs market is witnessing robust growth, fueled by rising awareness, enhanced diagnostic advancements, and the emergence of highly effective treatment options. A notable increase in the prevalence of Hepatitis C infections among various demographics has intensified the demand for potent antiviral therapies, particularly given the disease's potential to lead to serious chronic liver conditions. The focus on eradicating Hepatitis C by governments and healthcare organizations worldwide further accelerates market expansion. The elderly population's high infection rates highlight the urgency for advanced treatment solutions. Public health initiatives are actively educating high-risk groups about the disease and available therapies. Technological innovations, particularly in direct-acting antivirals (DAAs), have transformed the landscape, offering high cure rates and improved compliance through pan-genotypic and fixed-dose combinations, thereby enhancing treatment accessibility globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hepatitis C Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hepatitis C Drugs Market Segments Analysis

The hepatitis C drugs market is segmented based on drug class, routes of administration, disease type and region. In terms of drug class, the market is segmented into direct acting antivirals (NS3/4A protease inhibitor, NS5A inhibitor, NS5B polymerase inhibitor), combination therapy, interferons, and others. Based on routes of administration, the market is segmented into oral, injectable, and others. Based on disease type, the market is bifurcated into chronic hepatitis C and acute hepatitis C. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Central & South America and the Middle East & Africa.

Driver of the Global Hepatitis C Drugs Market

The growing prevalence of hepatitis C worldwide, driven by elements like intravenous drug use and inadequate medical practices, is significantly boosting the need for effective therapeutic options. This increased recognition of the disease, stemming from various risk factors and lifestyle changes, is creating greater urgency for innovative treatment solutions. As more individuals are diagnosed and seek care, healthcare systems are challenged to provide accessible and effective therapies. Additionally, increasing awareness about the importance of early detection and treatment is driving the momentum for advancements in the hepatitis C drug market, encouraging the development and availability of new treatment alternatives.

Restraints in the Global Hepatitis C Drugs Market

A major challenge hindering the widespread treatment of hepatitis C is the high cost of direct-acting antiviral (DAA) medications, especially in regions where financial resources are limited. Many healthcare systems face stringent budget constraints, which pose significant obstacles to achieving universal access to treatment. Although efforts to foster competition and engage in negotiations with government entities have led to some reductions in prices, these measures often fall short in making the medications financially accessible for all patients in need. Consequently, the affordability of hepatitis C drugs remains a critical barrier to effective treatment on a global scale.

Market Trends of the Global Hepatitis C Drugs Market

The global Hepatitis C drugs market is witnessing a transformative trend characterized by the growing availability of affordable Direct-Acting Antivirals (DAAs) and generics. As patents on several original DAAs expire and the landscape of voluntary licensing expands, a surge in low-cost treatment options is emerging, particularly benefiting low- and middle-income nations. This shift towards cost-effective therapies is crucial for accelerating treatment adoption, ultimately aligning with global health objectives to eliminate Hepatitis C. Additionally, enhanced accessibility to these treatments is fostering a more significant public health impact, paving the way for improved health outcomes and broader population coverage in combating this disease.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2025
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Case Studies
  • Customer Buying Behavior Analysis

Global Hepatitis C Drugs Market Size by Drug Class & CAGR (2026-2033)

  • Market Overview
  • Direct Acting Antiviral
    • NS3/4A Protease Inhibitor
    • NS5A Inhibitor
    • NS5B Polymerase Inhibitor
  • Combination Therapy
  • Interferons
  • Others

Global Hepatitis C Drugs Market Size by Routes of Administration & CAGR (2026-2033)

  • Market Overview
  • Oral
  • Injectable
  • Others

Global Hepatitis C Drugs Market Size by Disease Type & CAGR (2026-2033)

  • Market Overview
  • Chronic Hepatitis C
  • Acute Hepatitis C

Global Hepatitis C Drugs Market Size & CAGR (2026-2033)

  • North America (Drug Class, Routes of Administration, Disease Type)
    • US
    • Canada
  • Europe (Drug Class, Routes of Administration, Disease Type)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Drug Class, Routes of Administration, Disease Type)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Drug Class, Routes of Administration, Disease Type)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Drug Class, Routes of Administration, Disease Type)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2025
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2025
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

  • Pfizer (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AbbVie (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Gilead Sciences (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Roche (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Johnson and Johnson (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novo Nordisk (Denmark)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Hepion Pharmaceutical (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Vir Biotechnology (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teva Pharmaceutical (Israel)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol Myers Squibb (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations